Studie ROCKET AF - konec warfarinu na obzoru?
| Title in English | ROCKET study – Is the end of warfarin coming? |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Kardiologická revue |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | atrial fibrillation; warfarin; rivaroxaban |
| Description | ROCKET study – Is the end of warfarin coming? Anti-coagulation therapy is the basis of the treatment of atrial fibrillations in all their variations. This therapy consists in the administration of vitamin K antagonists, in our conditions warfarin. This requires strict INR monitoring, where INR < 2.0 means an inefficient treatment while INR > 3.0 means a high risk of haemorrhage. The American Heart Association considers studies involving drugs that are to replace warfarin in patients with atrial fibrillations to be one of the 10 most important discoveries of 2010. They are the RE-LY, ROCKET AF and AVEROES studies. The ROCKET AF study has demonstrated in 14,246 patients a trend towards a reduction in CMP and systemic embolisation in the treatment with rivaroxaban compared to warfarin, without increasing the haemorrhage risk. The number of incidents per 100 patient-years was 1.71 with rivaroxaban therapy and 2.16 with warfarin therapy (p < 0.001 for non-inferiority). In February 2011, the ARISTOTLE study with apixaban was completed and the ENGAGE study with edoxaban is in progress. |
| Related projects: |